Management of Idiopathic Intracranial Hypertension

Idiopathic intracranial hypertension (IIH) is characterised by elevated intracranial pressure without identifiable intracranial pathology and most commonly affects obese women of reproductive age. Management aims to preserve vision, alleviate headache and reduce cerebrospinal fluid accumulation. First-line strategies focus on weight management through structured dietary plans and lifestyle modification, often complemented by carbonic anhydrase inhibitors or topiramate to decrease cerebrospinal fluid production. In cases refractory to medical therapy or where vision is at imminent risk, surgical options include cerebrospinal fluid diversion via ventriculoperitoneal or lumboperitoneal shunts, optic nerve sheath fenestration and venous sinus stenting to improve cerebral venous drainage. Emerging protocols employ telemetric intracranial pressure monitoring to guide treatment thresholds and adapt interventions over time. Multidisciplinary teams comprising neurologists, neurosurgeons and ophthalmologists personalise care according to disease severity, comorbidities and patient preference. Recent shifts toward metabolic therapies underscore the importance of sustained weight reduction, both to modify disease course and to address associated cardiovascular risk factors.

Research from Nature Portfolio

No recent Nature Portfolio content available.

Management of Idiopathic Intracranial Hypertension publication trend

The graph below shows the total number of articles in management of idiopathic intracranial hypertension across all publications each year (not limited to Nature Index journals).

Technical terms

Intracranial pressure (ICP): The pressure exerted by cerebrospinal fluid within the cranial vault.

Cerebrospinal fluid (CSF): The clear fluid that circulates around the brain and spinal cord.

Papilloedema: Swelling of the optic disc resulting from raised intracranial pressure.

GLP-1 receptor agonist: A class of agents that mimic glucagon-like peptide-1 to promote weight loss and reduce CSF production.

Bariatric surgery: Surgical procedures intended to achieve significant and sustained weight reduction.

References

1. The effect of GLP-1RA exenatide on idiopathic intracranial hypertension: a randomized clinical trial. Brain (2023).
2. Treatment with GLP-1 receptor agonists is associated with significant weight loss and favorable headache outcomes in idiopathic intracranial hypertension. The Journal of Headache and Pain (2023).
3. European Headache Federation guideline on idiopathic intracranial hypertension. The Journal of Headache and Pain (2018).
4. Effectiveness of Bariatric Surgery vs Community Weight Management Intervention for the Treatment of Idiopathic Intracranial Hypertension. JAMA Neurology (2021).